The structural formula of chaulmoogric acid (C18H32O2) contains a cyclopent-2-en-1-yl group — a five-membered carbon ring with one double bond — at the end of a standard fatty acid carbon chain. This ring structure is found in a narrow range of natural fatty acids, all from the chaulmoogra family of plants. Its presence distinguishes chaulmoogra’s fatty acids from the more common saturated and monounsaturated fatty acids found in most other plant and animal oils.
The ethyl ester of chaulmoogric acid — the compound Ball was producing as the active component of her injectable preparation — is formed by replacing the carboxylic acid OH group with an -OEt group. The resulting ester retains the cyclopentenyl ring, which is presumed to be responsible for the biological activity, while changing the physical properties that determine injectability and absorption.
Ball was working with a mixture of these cyclopentenyl fatty acid esters rather than a single pure compound. Separating individual fatty acid esters from the mixture was not necessary for the therapeutic application; the mixture of ethyl esters from chaulmoogra oil’s fatty acids was the effective preparation, and purifying individual components would have been both technically difficult and medically unnecessary. The clinical observation was that the mixture of esters worked; identifying which specific ester was responsible for the effect was a question for future research rather than an immediate practical concern.
—
## Dapsone and the End of the Chaulmoogra Era
The transition from chaulmoogra preparations to dapsone (4,4′-diaminodiphenylsulfone) as the standard treatment for Hansen’s disease happened over roughly a decade, from the late 1930s to the late 1940s. The story of dapsone’s development is itself a complicated one, involving research in multiple countries and the eventual recognition that sulfone drugs could inhibit *M. leprae* at concentrations achievable with oral dosing.
